169 related articles for article (PubMed ID: 32074405)
1. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.
Martin-Romano P; Castanon E; Ammari S; Champiat S; Hollebecque A; Postel-Vinay S; Baldini C; Varga A; Michot JM; Vuagnat P; Marabelle A; Soria JC; Ferté C; Massard C
Cancer Med; 2020 Apr; 9(8):2643-2652. PubMed ID: 32074405
[TBL] [Abstract][Full Text] [Related]
2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.
Gauci ML; Lanoy E; Champiat S; Caramella C; Ammari S; Aspeslagh S; Varga A; Baldini C; Bahleda R; Gazzah A; Michot JM; Postel-Vinay S; Angevin E; Ribrag V; Hollebecque A; Soria JC; Robert C; Massard C; Marabelle A
Clin Cancer Res; 2019 Feb; 25(3):946-956. PubMed ID: 30297458
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
6. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
7. Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier A; Baldini C; Castanon E; Martin P; Champiat S; Hollebecque A; Postel-Vinay S; Varga A; Bahleda R; Gazzah A; Michot JM; Ribrag V; Armand JP; Marabelle A; Soria JC; Massard C; Ammari S
Cancer Immunol Immunother; 2021 Jan; 70(1):221-232. PubMed ID: 32700090
[TBL] [Abstract][Full Text] [Related]
8. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
[TBL] [Abstract][Full Text] [Related]
9. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
[TBL] [Abstract][Full Text] [Related]
10. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
11. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
Fujita K; Yamamoto Y; Kanai O; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T
Thorac Cancer; 2020 Jan; 11(1):15-18. PubMed ID: 31701630
[TBL] [Abstract][Full Text] [Related]
12. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.
Refae S; Gal J; Ebran N; Otto J; Borchiellini D; Peyrade F; Chamorey E; Brest P; Milano G; Saada-Bouzid E
Invest New Drugs; 2020 Feb; 38(1):160-171. PubMed ID: 31402427
[TBL] [Abstract][Full Text] [Related]
13. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Mönch S; Heimer MM; Winkelmann M; Guertler A; Schlaak M; Tufman A; Ben Khaled N; de Toni E; Westphalen CB; von Bergwelt-Baildon M; Dinkel J; Kazmierczak PM; Ingrisch M; Mansour N; Unterrainer M; Heinzerling L; Ricke J; Kunz WG
Cancer Imaging; 2023 Jun; 23(1):58. PubMed ID: 37291665
[TBL] [Abstract][Full Text] [Related]
14. Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Guiard E; Baldini C; Pobel C; Assi T; Bernard-Tessier A; Martin-Romano P; Hollebecque A; Verlingue L; Geraud A; Michot JM; Armand JP; Soria JC; Massard C; Ammari S
Eur J Cancer; 2022 May; 167():42-53. PubMed ID: 35378410
[TBL] [Abstract][Full Text] [Related]
15. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
[TBL] [Abstract][Full Text] [Related]
16. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
17. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
19. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
20. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Ichihara E; Harada D; Inoue K; Sato K; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Lung Cancer; 2020 Jan; 139():140-145. PubMed ID: 31786476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
